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Edited by Christos StournarasAbstract Transforming growth factor b (TGF-b) regulates cel-
lular behavior in embryonic and adult tissues. TGF-b binding to
serine/threonine kinase receptors on the plasma membrane acti-
vates Smad molecules and additional signaling proteins that
coordinately regulate gene expression or cytoplasmic processes
such as cytoskeletal dynamics. In turn, the activity and duration
of the Smad pathway seems to be regulated by cytoskeletal com-
ponents, which facilitate the shuttling process that segregates
Smad proteins in the cytoplasm and nucleus. We discuss mecha-
nisms and models that aim at explaining the coordination be-
tween several components of the signaling network downstream
of the TGF-b signal.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The transforming growth factor b (TGF-b) pathway plays
important roles in regulating cell physiology during embryonic
development and adult life, and perturbation of this pathway
is linked to a plethora of human diseases [1]. Here, we focus
on speciﬁc aspects of signal transduction regulation and on se-
lected physiological outputs of TGF-b. We highlight the mech-
anisms and importance of nucleocytoplasmic shuttling of
Smad molecules in maintaining the potency of TGF-b signal-
ing, and we review links of this pathway with regulation of
the cytoskeleton. These two aspects are currently investigated
with an increasing pace.Abbreviations: ALK, activin receptor-like kinase; aSMA, a-smooth
muscle actin; BMP, bone morphogenetic protein; Dpp, decapentaple-
gic; EMT, epithelial-mesenchymal transition; FGF, ﬁbroblast growth
factor; GDF, growth diﬀerentiation factor; GEF, guanine exchange
factor; GSK3b, glycogen synthase kinase 3b; MAPK, mitogen-
activated protein kinase; NES, nuclear export signal; NLS, nuclear
localization signal; PI3K, phospho-inositide 30-kinase; RTK, receptor
tyrosine kinase; SBE, Smad-binding element; TAK1, TGF-b-activated
kinase 1; TGF-b, transforming growth factor b
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In humans, TGF-b represents a family of secreted polypep-
tides that include 33 distinct gene products, most of which form
disulﬁde-bonded homodimers and some of which are also capa-
ble of forming heteromeric ligands [1]. Biosynthesis of TGF-b
mRNA, its protein in the endoplasmic reticulum, its secretion
through the Golgi apparatus and the exocytic vesicular system,
and storage in the extracellular matrix, is a complex process
that imparts several regulatory steps [2]. The matrix-stored
form of latent TGF-b requires biochemical activation, via pro-
teolytic cleavage, interaction with integrins and mechanochem-
ical force, such as that generated by myoﬁbroblast contraction,
before recognizing its cognate cell surface receptors [3,4].
The TGF-b family, in addition to the three TGF-b members
(TGF-b1, -b2, -b3), includes the bone morphogenetic proteins
(BMP), many of which are also named growth diﬀerentiation
factors (GDF), some unique GDFs, the anti-Mu¨llerian hor-
mone (AMH), the activins, inhibins, and nodals [1]. All these
ligands signal via a small number of cell surface receptors
and are involved in numerous physiological processes during
embryogenesis and organ formation as well as tissue homeo-
stasis in adults.
Especially during embryogenesis, but possibly during adult
tissue homeostasis as well, the secreted TGF-b ligands travel
certain distance from the producer cells to the responder cells,
and thus form morphogenetic gradients [5,6]. Ligand gradients
are regulated by complementary mechanisms, such as, cell-spe-
ciﬁc secretion across the tissue, gradients of antagonistic extra-
cellular proteins that bind and inactivate the ligands, and
gradients of proteases that degrade the extracellular antago-
nists and release bioactive ligands [7]. One model that explains
the mechanics of ligand gradient formation proposes a mech-
anism of transcytosis in the wing imaginal disc of Drosophila,
whereby the BMP-like ligand decapentaplegic (Dpp) is endo-
cytosed by the ﬁrst cell, without inducing its signaling path-
way, and then exocytosed from the opposite side of the same
cell in order to be engulfed by the neighboring adhering cell,
and thus Dpp travels across the multicellular embryonic tissue
in vesicles through the main cell body and via cell–cell junc-
tions [8]. According to another model, in early mouse embryos,
the secreted ligand Nodal travels along the basolateral cell sur-
face, always in association with plasma membrane-tethered
sulfated glycosaminoglycans, until it reaches its end target cell
where signaling initiates germ layer speciﬁcation and subse-
quent morphogenesis [9]. What deﬁnes the target cell that will
initiate Dpp or Nodal signaling according to these two models
remains currently unknown, but has been proposed to dependblished by Elsevier B.V. All rights reserved.
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the transducers of the Dpp/Nodal signal, the Smad proteins,
or their nuclear residence [10,11]. Currently, none of the above
models explain this important question.
TGF-b family studies in developing embryos of Drosophila,
Xenopus and the mouse, have emphasized the need for regula-
tion of signal strength and duration [6]. This concept is not un-
ique to TGF-b, and has been analyzed in more detail, e.g. in
the mitogen activated protein kinase (MAPK) pathway down-
stream of various mitogenic factors [12]. However, the
mechanics of how extracellular TGF-b signals are interpreted
in a quantitative and time-dependent way remain largely unex-
plained. Signiﬁcant recent advances in understanding such dy-
namic processes are underway [13].3. Signaling via TGF-b receptors
The TGF-b family signals via the small family of receptor ser-
ine/threonine kinases that include 7 type I and 5 type II receptors
[14]. All 12 receptors are single-pass transmembrane proteins
with a short cysteine-rich extracellular, ligand-binding domain,
an a-helical transmembrane domain and a long cytoplasmic do-
main that primarily consists of the kinase and secondarily of
additional protein sequences that serve either as phospho-accep-
tor sites or as docking sites for interacting adaptor or signaling
proteins. The 7 type I receptors are best known as activin recep-
tor-like kinases 1 to 7 (ALK1–ALK7) and each of them serves
the signaling needs of multiple ligands of the TGF-b family
[14]. The 5 type II receptors are the two activin/BMP receptors
ActRIIA, ActRIIB, the BMP receptor BMPRII, the TGF-b
receptor TGFbRII and the AMH receptor AMHRII [14].
During biosynthesis and traﬃcking from the endoplasmic
reticulum to the plasma membrane, ALK5 and TGFbRII
can form non-covalent, non-signaling homodimers [15,16].
The dimeric ligand provides two pairs of distinct binding sites
for each pair of receptor, and stabilizes a hetero-tetrameric
receptor complex presumably after appropriate rotation of
each receptor along the plane of the plasma membrane [17].
The stable hetero-tetrameric complex then signals and is inter-
nalized to the endosome. The assembly of the TGF-b receptor
diﬀers from the assembly of the BMP receptor complex [17].
The TGF-b ligand binds to TGFbRII and then ALK5 is
recruited to the complex in a cooperative manner, by making
contacts with both ligand and speciﬁc sequences of TGFbRII,
which stabilize the complex and are critical for signal transduc-
tion. The BMP type II and type I receptors make distinct con-
tacts with the ligand in the absence of receptor–receptor
contacts or cooperative assembly, and the localization of the
BMP receptors in plasma membrane regions is thought to
drive their assembly. Factors that regulate assembly of the het-
ero-tetrameric receptor complex are of signiﬁcance for signal-
ing and might contribute to abnormal signaling during
disease, such as cancer. Examples include the neurotrophin
receptor TrkC and better so its oncogenic form that binds to
TGF-b and BMP type II receptors and blocks formation of
functional receptor complexes [18,19]. In a distinct manner,
the pseudoreceptor BAMBI, which lacks a proper kinase do-
main, associates with TGF-b, activin and BMP type II recep-
tors and limits proper signaling via normal type I receptors
during development [20]. BAMBIs expression is suppressedin the ﬁbrotic liver, which promotes the pro-ﬁbrotic actions
of TGF-b signaling [21].
Eﬃcient ligand coordination with the two receptor kinases is
often facilitated by accessory receptors that can act in various
modes: they can recruit bioactive ligand to the vicinity of the
signaling receptor based on their higher aﬃnity for the ligand,
they can form complexes with the signaling receptors and
ligand, and they can also bind to extracellular antagonists thus
facilitating the binding of ligands to the receptor kinases. Such
co-receptors include plasma membrane tethered proteoglycans
(e.g. the TGF-b type III receptor betaglycan that also binds to
inhibin and BMPs) [22,23], glycoproteins (e.g. the TGF-b type
III receptor endoglin that modulates TGF-b and BMP signals
in endothelial cells) [2], or glycosyl-phospho-inositol-linked
receptors (e.g. the Nodal co-receptor Cripto that also binds
TGF-b and inhibits its signaling pathway) [24].
When TGF-b ligands bind to the signaling receptor kinases,
then the type II receptor, which has a constitutively active ki-
nase activity, trans-phosphorylates the GS (glycine-serine)-rich
segment proximal to the transmembrane domain of the type I
receptor, at multiple serine residues (Fig. 1) [25]. This trans-
phosphorylation reaction changes the conformation of the
GS domain, which unfolds and results in the release of nega-
tive regulatory chaperones such as FKBP12, thus allowing fur-
ther conformational change of the type I receptor kinase
domain and hence, its catalytic activation. The activated type
I receptor then catalyzes phosphorylation of downstream sig-
naling eﬀectors of the Smad family (Fig. 1). In addition, the
activated type I receptor catalyzes many other signaling events,
as we discuss below. Thus, the type I receptor is an essential
molecule in the signaling ﬂaw downstream from the ligand-
type II receptor complex. Although the functional attributes
of the type II receptors appear somewhat limited, recent exam-
ples reveal novel functions for these receptors. For example,
TGFbRII directly phosphorylates the polarity protein Par6,
which destroys epithelial polarity and induces a migratory cell
phenotypes (Fig. 1) [26]. Moreover, TGFbRII can be phos-
phorylated by the tyrosine kinase Src, which leads to recruit-
ment of the adaptor protein Grb2 to the receptor, and
assembly of signaling complexes that regulate receptor func-
tion, tumor cell migration and invasiveness [27].4. Smad molecules form a central intracellular engine
The activated type I receptor directly phosphorylates the C-
terminal di-serine motif of members of the Smad family [28].
These receptor-activated Smads (R-Smads) exhibit speciﬁcity
in their interaction with type I receptors in the family and thus
allow a classiﬁcation of the signaling pathways. Accordingly,
the R-Smads Smad2 and Smad3 recognize the L45 loop region
of ALK4, ALK5 and ALK7 (type I receptors for TGF-b,
activins, and some of the GDFs, e.g. GDF8/myostatin), while
the R-Smads Smad1, Smad5 and Smad8 show speciﬁcity for
the L45 loop of ALK1, ALK2, ALK3 and ALK6 (type I
receptors for BMPs, GDFs and AMH) [29–31].
C-terminal phosphorylation of the R-Smads leads to a con-
formational change of the whole protein and primarily of the
C-terminal conserved domain, called Mad-homology 2
(MH2) domain [25]. This conformational change allows the
phosphorylated R-Smad to oligomerize with itself or with
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Fig. 1. The TGF-b signaling pathway with Smad and non-Smad branches. Dimeric TGF-b binds to its type II (RII) and type I (RI) receptors,
inducing trans-phosphorylation (arrow) of RI by RII. RII phosphorylates the polarity protein Par6, which regulates Rho GTPase degradation and
actin dynamics. RI phosphorylates the adaptor ShcA, which leads to the activation of the Ras-MAPK Erk1/2 pathway (multiple arrows) that feeds to
the various gene responses of the pathway. RI phosphorylates R-Smads that oligomerize with Smad4 and regulate transcription in the nucleus. One
of the target genes of the pathway is the inhibitory Smad7, which blocks TGF-b signaling at multiple levels (R-Smad phosphorylation by RI, Smad
oligomerization and degradation, nuclear Smad activity). RI or RII (not yet known-dotted arrow) activate TAK1, which activates MEKK4 and
downstream MAPK p38, also providing signals to gene regulation. Smad7 plays a positive role in activation of the TAK1 cascade.
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Smad family proteins, the Co-Smad, which is represented by
a unique gene product in mammals, the Smad4 (Fig. 1). Smad4
is not phosphorylated by the type I receptors and characteris-
tically lacks the C-terminal di-serine motif [28]. However,
Smad4 has a highly conserved C-terminal MH2 domain that
interacts with the active conformation of the MH2 domain
in the phosphorylated R-Smads, as proven by crystallographic
studies of Smad1, Smad2, Smad3 and Smad4 [25]. The hetero-
oligomer of R-Smads with the Co-Smad has been crystallized
as dimer or trimer. Based on the trimer model, two phosphor-
ylated R-Smads assemble with one Smad4, as Smad4 replaces
one of the phosphorylated R-Smads in the R-Smad homo-tri-
mer [32].
The R-Smad/Co-Smad oligomers can assemble either in the
cytoplasm or in the nucleus, since all Smad proteins continu-
ously shuttle in and out of the nucleus as we discuss later.
Whether there is functional signiﬁcance ascribed to the location
of assembly of the oligomeric Smads is an interesting open
question. The Smad oligomer serves as a molecular platform
for the organization and execution of many nuclear reactions
that instruct the chromatin how to regulate transcription of a
multitude of gene targets (Fig. 1), which are diﬀerent from tis-
sue to tissue and from organism to organism. Context-depen-
dent responses demand an integration of information about
the developmental status of the responding cell and this is
achieved by various post-translational modiﬁcations of the
Smad complex in the nucleus. Molecular information is relayedby the Smad complex to chromatin by at least three speciﬁc
ways: binding to DNA, interaction with other DNA-binding
transcription factors, and association with chromatin remodel-
ers and transcriptional co-activators or co-repressors [25].
Smads bind with low aﬃnity to DNA sequences named the
Smad-binding elements (SBEs) that include the minimal motif
5 0-GTCT-3 0 or its complementary 5 0-AGAC-3 0, to which pri-
marily Smad3 binds, or a loosely deﬁned G/C-rich motif to
which Smad4 and BMP-speciﬁc R-Smads seem to bind [25].
The DNA-binding domain of Smads resides in their conserved
N-terminal MH1 domain and consists of a b-hairpin loop
structure. Smad2, one of the R-Smads of the activin/TGF-b/
nodal family, is expressed in two alternatively spliced forms,
a long form and a shorter form that lacks exon 3 (Dex3 form).
Exon3 of Smad2 provides a unique amino acid sequence in
very close apposition to the b-hairpin loop, which is thought
to perturb the structure of the b-hairpin loop so that full length
Smad2 fails to bind to DNA [34,35]. In contrast, the shorter
Dex3 form of Smad2 binds the same SBE as that deﬁned for
Smad3, with essentially the same aﬃnity. Binding of Smads
to DNA can be negatively regulated by phosphorylation of
the MH1 domain of Smad2 or Smad3 by kinases such as pro-
tein kinase C or calcium-calmodulin kinase II [36,37], and it
can be positively regulated by acetylation of the MH1 domain
of Smad2 Dex3 or Smad3 by acetyl-transferases such as p300,
CBP and P/CAF [38,39]. Whether there is an inverse link
between phosphorylation and acetylation of the Smad MH1
domain remains unexplored. In general, regulation of Smad
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exploration.
The Smad-interacting transcription factors provide the nec-
essary means for speciﬁcity or selectivity of the target gene reg-
ulatory elements, as the SBEs are highly abundant throughout
the genome, yet each of the various TGF-b family signaling
pathways regulates roughly 300–500 target genes in a given cell
type [40]. Genome-wide information of Smad-chromatin asso-
ciation is still missing despite the availability of chromatin
immunoprecipitation-genomic microarray technology (ChIP-
on-chip). In association with the many available transcriptomic
data sets, genome-wide location analyses will provide a more
robust framework for the understanding of how TGF-b path-
ways relay their signals to the genomes of responding cells. Re-
cent in vitro evidence has also highlighted the importance of
properly assembled chromatin for the ability of Smad com-
plexes to mediate transcriptional regulation [41]. This is unlike
other transcription factors that can stimulate transcriptional
initiation from naked DNA templates in vitro, and is probably
consistent with the low aﬃnity binding of Smads to naked
DNA. The chromatin-based transcriptional function of Smads
is determined by their association with chromatin remodeling
proteins such as Brg1, a component of the SWI/SNF complex
[41,42], ARC105, a mediator complex [43], and p300, CBP, P/
CAF, mSin3 and CtBP, general co-activators and co-repressors
that recruit histone acetyl-transferases and deacetylases [44].
Based on the above mechanisms, the Smad pathway regu-
lates a number of transcriptomic programs, like for example
the cytostatic (epithelial, endothelial or lymphocyte cell cycle
arrest), the apoptotic, the migratory, the transcriptional or
the negative feedback programs [40]. This aspect of TGF-b sig-
naling has been thoroughly reviewed over the past few years
[14,40,44–46].5. Feedback by inhibitory Smads
One of the best understood immediate-early gene targets of
TGF-b, activin and several BMP pathways is the gene encod-
ing the inhibitory Smad7 (I-Smad) (Fig. 1) [47,48]. Smad7 to-
gether with its relative Smad6 constitute the most divergent
Smad members, with a poorly conserved N-terminal domain,
only distantly related to the MH1 domains of other Smads,
a middle linker and a highly conserved C-terminal MH2 do-
main [28]. I-Smads, like Smad4, lack the C-terminal di-serine
motif and are not phosphorylated by the type I receptors.
Smad7 is the best studied among the two I-Smads. Smad7
resides in the nucleus and in addition to its transcriptional
induction, TGF-b signaling mobilizes a translocation of
Smad7 from the nucleus to the cytoplasm [49]. Smad7 is ex-
ported to the cytoplasm together with its companion E3 ubiq-
uitin ligases Smurf1 and Smurf2, and eventually associates
with the signaling receptor complex [50–52]. Binding of Smad7
to the type I receptors competitively blocks the recruitment of
R-Smads to the same receptors, and thus gradually reduces
phosphorylation and activation of the R-Smads (Fig. 1) [53].
Smad7 bound to the type I receptor ALK5 also recruits the
phosphatase PP1a which dephosphorylates ALK5, and thus
downmodulates its signaling activity [54,55]. Furthermore,
Smad7 brings its associated ubiquitin ligases Smurf1 and
Smurf2 to the receptor complex [50,51]. This leads to receptor
ubiquitination, which promotes receptor internalizationthrough lipid rafts and eventual receptor degradation in lyso-
somes (Fig. 2) [56].
Smad7 and Smad6 can form complexes with other Smad
proteins, especially with Smad4; this leads to dissociation of
the R-Smad/Co-Smad complexes (Fig. 1) [57], and also modu-
lates ubiquitination and degradation of R-Smads and Co-
Smads found in these common complexes [58]. Finally, Smad7
inhibits TGF-b signaling in the nucleus, by binding to Smad-
transcription factor complexes on chromatin, and blocking nu-
clear transmission of the TGF-b signal (Fig. 1) [59]. Thus, I-
Smads represent multifaceted adaptor proteins that organize
several negative regulatory reactions that ensure downregula-
tion or shut down of TGF-b signaling.
Despite this prominent role of I-Smads as negative regula-
tors, recent evidence illustrates the importance of Smad7 as
an organizer of additional signaling proteins around the type
I receptor, that lead to regulation of MAPKs and Rho GTP-
ases, during apoptotic and cytoskeletal responses to TGF-b
(Fig. 1) [60,61]. The mechanism that causes the switch of
Smad7 from a negative to a positive regulator of TGF-b sig-
naling might well rely on diﬀerences in the timing of events,
post-translational modiﬁcations of Smad7, and recruitment
of yet uncharacterized regulatory proteins to the type I recep-
tor, an area worth investigating deeper.6. TGF-b receptors activate additional, non-Smad signaling
eﬀectors
While signaling downstream of TGF-b family receptors
ﬁrmly involves the Smads, growing evidence places additional
signaling eﬀectors operating under the control of these recep-
tors [62]. Recently, clear links between the activity of the type
I and type II receptors via phosphorylation or direct docking
of such eﬀector proteins have been made. Since this topic
has also been abundantly reviewed [62,63], we highlight here
only few examples that illustrate distinct mechanistic para-
digms of signaling by the TGF-b family receptors to proteins
diﬀerent than the Smads.
Possibly the two most direct links between TGF-b receptors
and alternative signal transducers involve the phosphorylation
of new substrates by the receptors. As summarized above, an
alternative substrate of the TGFbRII is the polarity complex
protein Par6 [26]. ALK5 resides in tight junctions of polarized
epithelial cells and makes complexes with integral components
of the tight junction such as occludin [26]. TGFbRII resides in
association with E-cadherin in adherens junctions [64]. When
the signaling receptor complex forms, TGFbRII phosphory-
lates Par6, which leads to recruitment of the ubiquitin ligase
Smurf1 (also described under the negative control of TGF-b
receptors by Smad7); Smurf1 now ubiquitinates a novel sub-
strate, the small GTPase RhoA, which regulates the dynamics
of tight junction assembly and also the cytoskeleton that di-
rectly supports the assembly and function of such junctions
(Fig. 1) [26]. Proteasomal degradation of RhoA mediates tight
junction dissolution and architectural remodeling of the epi-
thelial cell as we discuss later.
A second prominent example is based on the intrinsic and
weak tyrosine phosphorylation activity of ALK5 and
TGFbRII. The functional relevance of tyrosine auto-phos-
phorylation by TGFbRII remains elusive [65]. In contrast,
ALK5 phosphorylates the adaptor protein ShcA on tyrosine
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ShcA then recruits Grb2 via its Src homology 2 domain, which
then mobilizes the well known MAPK signaling cascade. The
biological context under which TGF-b might choose to signal
via this ShcA-Grb2-MAPK pathway in parallel to the activa-
tion of the Smad pathway requires deeper understanding.
A third example is the activation of the TGF-b-activated ki-
nase 1 (TAK1) by TGF-b and BMP receptors (Fig. 1). TAK1
is a MAPK kinase kinase and despite its original discovery as
signaling eﬀector of TGF-b receptors [67], it has been ﬁrmly
linked to the signaling of pro-inﬂammatory interleukins and
Toll-like receptors [68]. TAK1 represents a special type of
kinase whose activity is regulated by ubiquitination during reg-
ulation of the pro-inﬂammatory NF-jB pathway. During
TGF-b signaling, TAK1 activates the downstream MAPK
p38 and plays important roles in the induction of apoptosis
in tumor and normal cells [60,69]. Interestingly, one link be-
tween TAK1 and the TGF-b receptors has been shown to be
the adaptor protein Smad7, which directly binds to ALK5
and to TAK1 [60]. TAK1 also signals downstream of BMP
receptors and the E3 ubiquitin ligase and inhibitor of apopto-
sis XIAP has also been linked in this pathway [70]. TAK1 sig-
naling downstream of BMP receptors plays roles during early
Xenopus development and a mechanism leading to speciﬁc acti-
vation of the TAK1-p38 MAPK signaling cascade is the olig-
omerization of BMP receptors in response to ligands [71]. Of
higher importance though will be the elucidation of a molecu-lar mechanism by which the TGF-b or BMP receptors might
regulate the catalytic activity of TAK1 so that its downstream
signaling cascade is mobilized. Such a mechanism might in-
volve direct phosphorylation by the receptors, or alternatively,
it might involve signaling complex assembly based on adaptor
proteins like Smad7. The recent evidence that TAK1 directly
interacts with TGFbRII and indirectly with ALK5 does not
yet solve this exciting open problem [72].7. Coordinated signaling by Smad and non-Smad pathways
A frequent question in the understanding of TGF-b path-
ways is the relative contribution of Smads and alternative eﬀec-
tors during a particular biological process. One possibility is
that Smad signaling primarily aﬀects transcriptional regula-
tion, whereas non-Smad signaling might modulate cytoplasmic
processes. The true picture points to integration of several
pathways. For example, TGF-b or BMP signaling via TAK1
and p38 MAPK contributes to speciﬁc gene regulation in par-
allel to Smad signaling [73]. On the other hand, TAK1 was
found to interact with all Smad proteins and thus, to nega-
tively regulate Smad signaling and its eﬀects on osteogenesis
[74]. TAK1 also phosphorylates and regulates the stability of
the Smad-interacting protein SnoN [75], which acts as an onco-
gene or tumor suppressor by regulating various facets of Smad
signaling in the cytoplasm and the nucleus [76]. TGF-b, via
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tion of SnoN, which allows robust nuclear Smad signaling, as
SnoN generally represses the transcriptional activity of Smads.
However, TAK1 also enhances SnoN degradation [75], and it
is worth examining whether phosphorylation of SnoN by
TAK1 might be a priming event required for the Smad-depen-
dent recruitment of ubiquitin ligases to SnoN.
Thus, Smad and non-Smad signaling seem to coordinate
common target events. A good example illustrating this model
is based on the structurally ﬂexible linker domain of Smad pro-
teins, that links the N-terminal MH1 with the C-terminal MH2
domains [28]. The linker domain is proline- and serine/threo-
nine-rich. MAPKs such as Erk1 and Erk2 [77,78], cyclin-
dependent kinases [79], and synthase glycogen kinase 3b
(GSK3b) [80,81], phosphorylate distinct and often multiple
amino acid residues within the linker domain of R-Smads such
as Smad1, Smad2 or Smad3. Linker phosphorylation seems to
be a priming event for the recruitment of the ubiquitin ligase
Smurf1 to speciﬁc proline-tyrosine motifs of the R-Smad linker
domain [80,84]. The Smurfs eventually ubiquitinate and de-
grade the R-Smads, thus leading to a shut oﬀ mechanism of
Smad signaling. This mechanism can be counteracted by phos-
phatases such as the small C-terminal domain phosphatases
(SCPs) that dephosphorylate the R-Smad linker and enhance
Smad signaling [82,83]. In Smad1, GSK3b phosphorylates
the linker, which is required for the subsequent phosphoryla-
tion of the linker by Erk1/2, which leads to Smad1 ubiquitina-
tion and proteolytic degradation in proteasomal factories
associated with the centrosome [80]. The stability of Smad3
is also regulated by GSK3b, which phosphorylates the MH1
and linker domains, but phosphorylation of the MH1 domain
rather than the linker seems to correlate better with Smad3
degradation [81]. Such mechanisms can partially explain an
antagonism of TGF-b signaling by mitogenic factor signaling
that activates Erk MAPK [77,78]. Accordingly, epidermal
growth factor, hepatocyte growth factor or ﬁbroblast growth
factor (FGF) or alternatively, oncogenic forms of Ras, a
downstream signaling protein of these mitogens that signal
via receptor tyrosine kinases (RTKs) and activate Erk1/Erk2,
lead to R-Smad linker phosphorylation and degradation, thus
negatively regulating the TGF-b pathway.
On the other hand, during development, TGF-b and FGF
signaling cooperate and FGF activates the CK1e/d kinases that
phosphorylate the tumor suppressor transcription factor p53
[85]. This phosphorylation enables p53 to associate with
Smads and regulate critical target genes that specify the meso-
dermal germ layer in Xenopus embryos or cell cycle inhibitor
genes like p21, that mediate epithelial growth arrest by TGF-
b. Thus, signaling pathways such as those initiated by RTKs
can either negatively regulate the Smads or positively activate
Smad co-factors such as p53. The time or context-dependence
of such cross-talk that deﬁnes binary choices of the TGF-b sig-
naling pathways requires critical future attention.
On a diﬀerent scenario, Smad3 directly interacts with other
signaling proteins, such as protein kinase A (PKA) or protein
kinase B (PKB/Akt), whose catalytic activities are directly reg-
ulated by the association with Smad3 [86–89]. Both of these ki-
nases participate in highly complex signaling cascades initiated
by alternative extracellular factors such as hormones and neu-
rotransmitters that signal via G-protein coupled receptors or
RTKs that in addition to MAPK cascades activate the phos-
pho-inositide 3 0-kinase (PI3K)-Akt pathway.These examples illustrate the highly integrated nature of sig-
naling cascades initiated by TGF-b family receptors. These
cascades provide cross-talking points with other signaling
pathways, and it seems that each one of these pathways
cross-checks the progression of signal transduction of the other
pathway. Positive and negative signaling inputs provide the
means for highly controlled and progressive signaling.8. TGF-b receptor traﬃcking
The TGF-b receptor complex is thought to reside in either
plasma membrane areas that assemble coated pits or in the so
called lipid rafts (Fig. 2) [56]. Single molecule measurements
of TGFbRII and ALK5 lateral diﬀusion concluded that heter-
omeric receptor assembly preferentially occurs at lipid rafts
[90]. In polarized epithelial cells, the receptors can be associated
with adherens and tight junctions as described above. In fact
adherens and tight junctions represent distinct microdomains
of the plasmamembrane that have major characteristics of lipid
rafts [91]. The dynamic distribution of the receptors within such
membrane microdomains could possibly be driven by underly-
ing cytoskeletal elements; however, this topic remains largely
underexplored. Only few reports so far shed some light to this
question. A dynein protein light chain subunit, the protein
km23-1, associates with signaling TGF-b type I receptors and
localizes in early endosomes [92]. km23-1 is functionally
required for physiological TGF-b signaling as examined by var-
ious biological assays. A diﬀerent dynein light chain subunit,
the protein Tctex2b, interacts with the accessory receptor
endoglin and TGFbRII and mediates their microtubule-based
transport [93]. Proper cellular levels of Tctex2b regulate
TGF-b/endoglin signaling in endothelial cells.
According to one prominent model, TGF-b receptor com-
plexes associated with coated pits endocytose towards early
endosomes [56,94], where R-Smads (of activin/TGF-b/nodal
pathways) are presented by endosomal proteins such as
SARA, resulting in R-Smad phosphorylation and activation
(Fig. 2) [95]. During BMP signaling, receptor internalization
by clathrin-mediated endocytosis is followed by R-Smad pre-
sentation to the receptors by the SARA-related protein endoﬁn
[95]. On the other hand, BMP receptor signaling towards the
TAK1-p38 pathway initiates from receptor complexes localiz-
ing in lipid rafts [96]. Diﬀerences between TGF-b and BMP
receptor localization on the plasma membrane may well be
associated with the diﬀerences in ligand–receptor assembly as
explained earlier. Our increasing understanding of the role of
TGF-b receptor endocytosis in promoting this signaling path-
way is also nicely illustrated by a recent report that identiﬁed
the Rab5 guanine exchange factor (GEF) called RIN1, as a
strong promoter of TGF-b signaling by enhancing receptor
endocytosis [97]. Furthermore, TGF-b signaling induces the
transcriptional repressor Snail, which directly represses expres-
sion of the RIN1 gene, thus providing another negative feed-
back mechanism for the time-dependent control of this
pathway. It should be emphasized that all traﬃcking pathways
are highly dynamic, and thus, deﬁning with accuracy whether
Smads get phosphorylated only on the plasma membrane, en
route to early endosomes or only in endosomes has been tech-
nically demanding and still not properly resolved.
According to the same model of TGF-b receptor internaliza-
tion, when ligand-bound receptors associate with lipid rafts,
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internalization via caveolae and degradation in lysosomes
(Fig. 2) [56]. However, as the various cytoplasmic traﬃcking
vesicles seem to communicate with each other, it will be inter-
esting to examine whether certain pools of receptors traﬃc be-
tween the endosomes and caveolae or vice versa, thus
providing feedback about biochemical events in each locale
(Fig. 2). The multifunctional role of Smad7 provides suﬃcient
reasons that would support such a model. The endosomal
route can also lead to the lysosome or alternatively generate
vesicles that either recycle to the plasma membrane or that
could even be fused to the endoplasmic reticulum-nuclear
envelope compartments. These are attractive possibilities not
yet investigated, whereby signaling TGF-b receptors could give
feedback to newly synthesized pools of TGF-b receptors, or
signal from the nuclear envelope.9. Nucleocytoplasmic shuttling of Smads and its control by the
cytoskeleton
The traﬃcking of components in the TGF-b signaling net-
work is even more perplexed when it comes to the Smads.
As we already described, Smad proteins shuttle between theR
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but involves dynein motors (Fig. 3). On the other hand, micro-
tubules have also been proposed to trap Smads in the cyto-
plasm, while their release can be regulated by proteins such
as connexin43, which competes for microtubule binding with
the Smads [101]. The possibility that such a mechanism pro-
vides a switch that regulates the mobility of Smads along
microtubules remains to be clariﬁed.
Microtubule assembly starts from organizing centers, such
as the centrosome. In fact, Smads have been shown to undergo
proteasomal degradation in centrosomes (Fig. 3) [80], associate
with the spindle in mitotic cells and also decorate chromo-
somes during metaphase. Interestingly, the protein comple-
mentation study in Xenopus embryos (summarized above),
revealed Smad2–Smad4 heteromeric complexes in association
with chromosomes, every time the embryonic cells divided,
and independent of whether these cells were responding to a
TGF-b family ligand [33]. This may reﬂect an eﬀort to properly
segregate Smads to daughter cells after mitosis or might sug-
gest that Smads regulate the process of mitosis and cytokinesis
per se. Drosophila embryos provide a positive lead in this direc-
tion, as epithelial cells of the wing imaginal discs contain endo-
somes enriched in the protein SARA, the ligand Dpp and its
type I receptor Thickveins. During each cell division of the
growing imaginal disc, the ligand–receptor–SARA complex to-
gether with endosomes segregate to daughter cells via microtu-
bules of the mitotic spindle [102]. This mechanism provides a
fresh clue as to how developing tissues can spread their
TGF-b signaling machineries across the organ and comple-
ments the processes of transcytosis and cell surface-mediated
transport of ligands. Thus, studying the subcellular distribu-
tion of Smads during the cell cycle of various cell types is an
appealing topic for present investigation.
Traﬃcking of Smads together with endocytic vesicles as mul-
timolecular protein complexes along microtubules, does not
capture the whole picture of Smad shuttling. Conserved, ly-
sine-rich nuclear localization signals (NLS) have been identi-
ﬁed in all Smads [28]. The NLS resides in the MH1 domain
very close to the DNA-binding b-hairpin loop and is recog-
nized by transporters, importin-b for Smad3 and importin-a
for Smad4 [103–106]. Transportin-dependent import of Smad3
has been proven by in vitro import assays in partially perme-
abilized cells with intact nuclei, while the biological relevance
of the NLS has been deﬁned by mutational experiments that
established the necessity of the lysine-rich motifs for Smad nu-
clear accumulation. Furthermore, the functional role of the
small GTPase Ran was ﬁrmly established by these in vitro as-
says [103]. Ran, in its GTP-bound form, facilitates the dissoci-
ation of Smad3 from importin-b in the nucleus and assists the
recycling of importin-b back to the cytoplasm (Fig. 3). Using
in vitro import assays, the necessity of speciﬁc transporters
was refuted, while Smad2, Smad3 and Smad4 were shown to
bind to the phenylalanine/glycine (F/G)-rich repeats of speciﬁc
nucleoporins of the nuclear pore (Fig. 3) [107,108]. Smad2 and
Smad3 contact nucleoporins via their MH2 domain hydropho-
bic surface, while Smad4 interacts with nucleoporins via a not
well deﬁned epitope on the surface of the whole protein. In vi-
tro import experiments of speciﬁc Smad domains mapped the
functional import activity of Smads (or in other words, a do-
main that could carry NLS-like activity) to the MH2 domain
instead of the MH1 domain. The direct physical interaction be-
tween the nucleoporin Nup214 and Nup153 F/G-repeat frag-ments was demonstrated only for the MH2 domain of
Smad2, but not for the corresponding domains of Smad3 or
Smad4 [107,108]. Interestingly, the transportins like impor-
tin-b, transport their cargo through the nuclear pore by mak-
ing multiple direct contacts with the F/G-repeats of the
nucleoporins. Thus, it is possible that Smads are transported
to the nucleus via speciﬁc transportins while also making direct
contacts with speciﬁc nucleoporins of the nuclear pore.
Smad2 is an interesting Smad, as its unique exon3 that per-
turbs binding to DNA, also perturbs its recognition by impor-
tin-b [103]. Thus, Smad2 would not be able to make contacts
with importin-b via its MH1 domain, while it could contact
the nucleoporins via the hydrophobic surface in its MH2 do-
main. Unfortunately, the NLS sequence of Smad2 has not
been mutated to examine the functional relevance of this motif
in the nuclear import of this protein in intact cells. Interest-
ingly, a recent RNAi-based screen for novel regulators of the
nuclear import of Mad, the Drosophila R-Smad of the Dpp
pathway, identiﬁed a novel transportin, moleskin, the Dro-
sophila homologue of two human transportins, importin-7
and importin-8 (Fig. 3) [109]. RNAi experiments in the ﬂy
clearly established the role of endogenous moleskin on nuclear
import of phosphorylated Mad and also the role of importin-7
and importin-8 on the nuclear import of Smad1, Smad2 and
Smad3 in human cancer cells in response to BMP or TGF-b
signaling, respectively. This latter study also excluded the role
of the Drosophila homologue of importin-b, ketel, in the nucle-
ar import of phosphorylated Mad in ﬂy cells, but unfortu-
nately did not test for the role of importin-b on import of
Smad1 or Smad3 in mammalian cells. These latest in vivo data
support an interesting model whereby constitutive Smad im-
port does not require transportins, and presumably is based
on direct contacts with nucleoporins, while nuclear import of
phosphorylated R-Smads, requires the transportins.
This conclusion brings us to an important current model
according to which, Smads continuously shuttle in and out of
the nucleus, and at any given moment, most of the Smad mol-
ecules distribute in the cytoplasm [13]. This model is based on
studies of Smad2 and Smad4 and remains to be applied to
Smad3 or to BMP-speciﬁc Smads. In addition, all kinetic anal-
yses rely on transfected GFP-tagged Smads that seem to
approximate rather well the behavior of endogenous Smads,
however, they represent a condition where the speciﬁc Smad
concentration has at least been doubled within the transfected
cells [98]. This kinetic analysis demonstrated that nuclear
export is a more critical determinant during Smad shuttling.
In other words, Smads enter the nucleus almost spontaneously
(presumably by utilizing their aﬃnity to nucleoporins), while
their export is a slower process. Thus, upon activation of
TGF-b pathways by ligands, activated R-Smad/Co-Smad com-
plexes accumulate in the nucleus because their nuclear export is
blocked (presumably by masking of speciﬁc nuclear export sig-
nals within the complex). The residence of the nuclear Smad
complexes then can be regulated by nuclear phosphatases such
as PPM1A (for Smad1, Smad2 and Smad3) [110,111], SCPs
(for Smad1) [112] and pyruvate dehydrogenase phosphatase
[113] that dephosphorylate the C-terminal di-serine motifs of
R-Smads, leading to monomeric Smads that follow their con-
stitutive shuttling cycle. Based on experiments with inhibitors
of the activin/TGF-b/nodal type I receptors, the nuclear resi-
dence of Smad complexes seems to depend on the time that
the TGF-b receptors remain active, since inhibition of the type
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throughout the cell [114]. This is an attractive model that
directly links the activity of the receptor complex to the relative
concentration of Smad complexes in the nucleus. It relies pri-
marily on cycles of phosphorylation and dephosphorylation
of the C-terminal di-serine motif, but it is likely that other
post-translational modiﬁcations of Smads also have important
roles, such as phosphorylation of the linker and other domains,
ubiquitination and local degradation, acetylation and de-acet-
ylation, or yet uncharacterized post-translational modiﬁca-
tions.
Despite its current incompleteness, the shuttling model
emphasizes the role of nuclear export of Smads. Indeed, nucle-
ar export signals (NES) were ﬁrst deﬁned in Smad4, which car-
ries a leucine-rich NES in its linker domain [115,116]. This
NES is recognized by exportin-1/CRM1 (Fig. 3), and when
mutated or when cells are incubated with the CRM1-speciﬁc
inhibitor leptomycin B, then Smad4 distributes exclusively in
the nucleus of cells that were either stimulated or not with li-
gands of the TGF-b family. One fact that contradicts the
importance of the Smad4 NES is based on the kinetic analysis
previously described, which suggests a steady-state Smad4 dis-
tribution that is both cytoplasmic and nuclear, and proposes
that the functionality of the Smad4 NES is regulated by un-
known mechanisms. Recently, the biological signiﬁcance of
Smad4 export and of the whole Smad shuttling model has been
challenged, since mice with a knock-in mutation in the Smad4
NES, which led to stronger nuclear residence of Smad4, did
not exhibit any obvious phenotype [117], suggesting that nucle-
ar export of Smad4 via this NES might not be of importance
for embryonic development and adult tissue homeostasis. In
analogy with Smad4, a bipartite, leucine-rich NES found in
the MH2 domain, regulates the export of Smad1 [118]. And ﬁ-
nally, a non-classical NES sequence residing also in the MH2
domain of Smad3 was shown to mediate its nuclear export
via the novel exportin-4 and with the catalytic power of the
Ran GTPase (Fig. 3) [119].
A related topic to the mechanisms of regulation of Smad
shuttling is the importance of tethering factors that might trap
Smads in the cytoplasm or the nucleus. Such roles have been
proposed for the endocytic protein SARA in the cytoplasm
[120], and for yet unidentiﬁed chromatin-associated factors
in the nucleus [98]. However, all current evidence disfavors
the existence of factors that completely trap Smad proteins
in a speciﬁc compartment. It is more likely that any protein
that associates with the Smads either in the cytoplasm or in
the nucleus might regulate the timing or residence of the Smad
in a speciﬁc cell compartment. Such regulatory proteins can be
TRAP-1, a Smad4 chaperone that controls the recruitment of
Smad4 to TGF-b receptors, TLP1 and Erbin, two Smad2 and
Smad3-interacting regulators, which limit the incorporation of
Smad2 or Smad3 into signaling complexes with the Co-Smad,
and ELAC2, a Smad2 nuclear partner that facilitates tran-
scriptional signaling [121–124].
Attractive systems that could regulate the mobility and func-
tion of Smads in the cell are cytoskeletal ﬁlaments and nucle-
oplasmic microdomains. However, with the exception of the
role of microtubules that seem to provide routes for the rapid
movement of Smads and/or vesicles carrying TGF-b receptors
in the cytoplasm, no other role of the actin microﬁlament sys-
tem, the intermediate ﬁlament system of keratins or vimentin
or of any speciﬁc regulator of nuclear architecture has yet beenreported. Thus, additional work on the topic of Smad traﬃck-
ing is needed before this aspect of regulation of TGF-b signal-
ing is fully understood.10. TGF-b controls the cytoskeletal machinery to induce cell
motility or changes in cell architecture
Although the role of cytoskeletal elements in modulating
TGF-b signaling has just started to emerge and relates primar-
ily to microtubules, TGF-b members have a strong and com-
plex impact on the organization of cytoskeletal architecture.
This primarily involves the actin cytoskeleton and secondarily
certain systems of intermediate ﬁlaments [1]. By targeting the
actin cytoskeleton, TGF-b signaling seems to aim at least at
two diﬀerent physiological outcomes that are interlinked: ﬁrst,
it changes the overall cellular architecture which has an impact
on diﬀerentiation and proliferation, and second, facilitates cell
motility, prerequisites of which is the altered architectural
arrangement and the remodeling of the extracellular matrix
to which the cell adheres and migrates on. The change in cel-
lular plasticity is most clearly seen in epithelial cells that under-
go epithelial–mesenchymal transition (EMT), a change in their
diﬀerentiation that promotes cell migration and is biologically
linked to embryonic tissue movements and to tumor cell inva-
siveness and metastasis [125]. During EMT, epithelial cell–cell
junctions are dissolved and the underlying actin cytoskeleton is
reorganized with prominent formation of focal adhesions and
stress ﬁbers interconnecting these focal adhesions so that
‘‘ameboid’’ movement of the mesenchymal cells is obtained.
During EMT, the intermediate ﬁlament system of cytokeratins
exchanges to new cytokeratins and to a vimentin-based skele-
ton. At least in the case of vimentin, we understand that Smad
signaling together with cooperating transcription factors in-
duces expression of its gene during mesenchymal diﬀerentia-
tion (Fig. 4) [126]. These changes are functionally associated
with induced cell mobility towards either a chemotactic gradi-
ent of TGF-b ligands or towards a gradient of other chemo-
attractants like platelet-derived growth factor or chemokines,
whose secretion is potently induced by the primary TGF-b
stimulus.
We already described the most prominent example of direct
signaling by the TGF-b receptors towards the small GTPase
Rho, a prominent regulator of actin cytoskeleton dynamics.
This mechanism entails phosphorylation of Par6 and ubiquiti-
nation by Smurf1 (Fig. 4) [26]. According to the mechanism,
TGF-b receptor signaling initiating at tight junctions leads to
local disassembly of actin microﬁlaments intimately associated
with the assembly of the junctions, which is required for their
eﬀective dissolution. However, direct demonstration of such
modulation of actin dynamics that support tight junction
assembly in response to TGF-b has not yet been reported. This
example illustrates an exciting area for future research. Instead
of measuring global eﬀects of TGF-b members on the actin
cytoskeleton, which has by now been reported repeatedly,
analysis of dynamic changes in subcellular compartments
promises the discovery of new mechanisms of regulation of cel-
lular architecture.
Not only RhoA protein levels can be locally degraded in re-
sponse to TGF-b, but more frequently signals by either TGF-b
or BMPs activate small GTPases of the Rho family (e.g. RhoA
or Cdcd42) and positively aﬀect the assembly of new actin
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cytoplasmic tail of the BMP type II receptor BMPRII directly
associates with the kinase Limk1 during morphogenesis of
dendrites by neuronal cells, and the process gets misregulated
in certain cases of pulmonary hypertension [127,128]. Binding
of Limk1 to BMPRII leads to activation of its kinase activity,
which then phosphorylates coﬁlin, a factor that depolymerizes
ﬁlamentous actin (Fig. 4). Phosphorylated coﬁlin is inhibited
and thus actin dynamics shift towards polymerization. In addi-
tion to the direct activation of Limk1 by the BMPRII, BMP
signaling also activates the Cdc42 GTPase, which also contrib-
utes to positive actin microﬁlament assembly [128].
During embryonic nerve growth cone path-ﬁnding, BMPs
again aﬀect Limk1 activity and coﬁlin phosphorylation as
cones are attracted towards the BMP source; however, when
growth cones reach higher concentrations of the BMP gradi-
ent, their receptors reach saturation and the cones are repelled
from the BMP source, at which point the coﬁlin phosphatase
slingshot becomes activated, and returns the equilibrium of
this pathway back to its starting stage [129]. This elegant mech-
anism is further regulated by the transient induction of a cal-
cium channel receptor, TRPC1, which leads to calcium-
dependent regulation of the calcineurin phosphatase that
dephosphorylates and activates slingshot. Similar to BMPRII,
ALK5 induces RhoA or RhoB GTPase activity, leading todownstream activation of the kinase ROCK1, which then
phosphorylates Limk2 in order for coﬁlin to be inhibited as de-
scribed above, and positively aﬀect actin polymerization in
ﬁbroblasts and epithelial cells (Fig. 4) [130]. Furthermore, in
breast cancer cells that exhibit enhanced motility and metasta-
sis in response to TGF-b, PI3K, the MAPKs Erk1/2 and the
small GTPase Rac1 promote actin organization and cell
migration, while in transformed ﬁbroblasts TGF-b induces
expression of RhoB in order to reorganize actin microﬁlaments
(Fig. 4) [131–133]. A similar interplay of MAPK and Rho
GTPase signaling has been established during physiological
migration of eyelid epithelial cells and keratinocytes in mice,
as demonstrated by knockout of the MAPK kinase MEKK1,
which activates downstream Jun-N-terminal kinase and p38
MAPKs to elicit such migration induced by TGF-b or activin
[134,135].
The best example of a Smad protein linked to the regulation
of Rho family GTPases and actin dynamics comes from pros-
tate cancer cells, where the inhibitory Smad7 acts as an adaptor
recruited to ALK5 in order for Cdc42 activity to be enhanced
(Fig. 4) [61]. In the same model, TGF-b also induces RhoA
and downstream p38 MAPK activation leading to actin poly-
merization [136]. This mechanism, together with the above
examples of Rho GTPase and Limk activation by TGF-b, raise
the possibility that TGF-b receptors may serve as organizing
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dynamics. However, a direct interaction of Rho GTPases or
the ROCK1 kinase with TGF-b receptors has not yet been
demonstrated. Alternatively, a Rho family GEF might directly
associate with TGF-b receptors, becoming activated possibly
via phosphorylation by the receptor and then activating a
Rho GTPase. A link with Rho family GEFs has already been
made, since the Smad3/Smad4 complex in cooperation with
Rho and p38 MAPK signaling downstream of TGF-b recep-
tors, on the one hand induces expression of the GEF NET1
(Fig. 4), which accumulates and promotes actin polymerization
[137], and on the other hand induces expression of tropomyo-
sins that regulate assembly of a contractile apparatus that
serves the motility of the responding cell during the EMT pro-
cess (Fig. 4) [138]. As TGF-b establishes the mesenchymal phe-
notype via EMT, it also triggers the nuclear translocation of
myocardin-related transcription factors (MRTFs), which inter-
act with Smads and regulate major transcriptional mediators of
EMT, such as the Slug repressor [139]. In addition, MRTFs
cooperate with serum response factor (SRF) in mediating tran-
scriptional induction of various components of the actin cyto-
skeleton, including tropomyosin I, caldesmon and a-smooth
muscle actin (aSMA).
In a parallel scenario, during EMT at the early stage of
embryonic gastrulation, activin/nodal-speciﬁc Smad signaling
induces expression of two cooperating proteins, the ﬁbronectin
leucine-rich repeat transmembrane 3 (FLRT3) and the small
GTPase Rnd1, which interact with each other and regulate
endocytosis of cadherin from adherens junctions [140]. This
process depletes cadherin, a hallmark of EMT, and facilitates
cell migration after actin reorganization. While EMT is a pro-
cess ascribed to epithelial cells, a variety of other cell types,
including endothelial cells and ﬁbroblasts can also undergo a
similar process that leads to their diﬀerentiation into myoﬁbro-
blasts. Smad signaling in response to TGF-b induces expres-
sion of the SM22a gene in association with the transcription
factor myocardin, or induces expression of the aSMA gene
in association with transcription factors YB-1 and Sp1
(Fig. 4) [141,142]. SM22a and aSMA are the most characteris-
tic proteins of smooth muscle cells as they build a new actin
cytoskeleton with more contractile properties that serves the
function of contracting myoﬁbroblasts. Finally, formation of
specialized actin structures, called podosomes, underneath
the plasma membrane of endothelial cells involves de novo
synthesis of cytoskeletal proteins and requires coordinated sig-
naling by the cytoplasmic tyrosine kinase Src, PI3K, Cdc42
and Smads [143]. Such podosomes become enriched in metal-
loproteases necessary for the remodeling of blood vessels.
Interestingly, two recent reports provide evidence that the
cytoskeleton, or some of its key regulators, can regulate
TGF-b pathways. In diﬀerentiating myoﬁbroblasts, TGF-b
activates RhoA, which regulates Smad nuclear accumulation
and transcriptional output in parallel to actin remodeling
(Fig. 4) [144]. On the other hand, BMPs induce myosin-X tran-
scription in endothelial cells and cause their migration during
vessel formation [145]. Interestingly, newly synthesized myo-
sin-X co-localizes with the BMP type I receptor ALK6 into ﬁl-
opodia, and the receptor-myosin-X complex becomes motile
(Fig. 4). This process is required for sustained Smad activation
in response to prolonged BMP signals, leading to a feedfor-
ward loop where BMP enhances cytoskeletal motility and
the motile cytoskeleton enhances BMP signaling. This excitingnew mechanism opens the road to new investigations that
might eventually establish a ﬁrm and potent role of cytoskele-
tal elements in the step-wise progression of the TGF-b signal-
ing pathway.11. Perspectives
In this article, we have highlighted specialized mechanisms
that operate during molecular signaling by TGF-b family
members. We have not covered all aspects of regulation of
these pathways; rather we gave emphasis on areas of current
and hopefully future active investigation. Such areas revolve
around the still open problem of receptor and Smad traﬃcking
and understanding the true biological meaning of such a com-
plex process. Identiﬁcation of novel regulators of traﬃcking is
a major prerequisite together with the development of more
sensitive cell biological tools that will allow the direct visuali-
zation of the dynamics of endogenous receptor and Smad
movements in live cells and in real time. This should be cou-
pled to approaches that examine the role of the cytoskeleton
not only as a system that responds to the incoming TGF-b sig-
nals, but also as a system that provides signaling feedback to
speciﬁc components of the pathway in order to cross-check
its physiological ﬂow.
The whole ﬁeld of TGF-b signal transduction currently re-
quires a thorough revisiting and clariﬁcation of the role of
the various post-translational modiﬁcations that occur on
either the receptors or the Smads. The emphasis must be on
the timing of these events and on the characterization of
sub-pools of the various protein complexes. The spectrum of
post-translational modiﬁcations and interacting protein regu-
lators of Smads and receptors will most certainly increase with
time. The ultimate analysis of the network will additionally re-
quire sophisticated mathematical tools that might provide
important predictions and aid in the elucidation of yet un-
known regulatory mechanisms of this pathway. Finally, as
the detailed knowledge of TGF-b signaling constantly in-
creases, we should not forget that the TGF-b family includes
many ligands. Not only is it important to elucidate the individ-
ual signaling details of each one of these – a task currently well
underway [1] – but we need to remember that most cell systems
are simultaneously or sequentially exposed to the action of sev-
eral ligands of this family. Thus, measuring eﬀects of TGF-b in
an epithelial cell requires the consideration of the exact contri-
bution of a parallel GDF pathway that is activated in the same
cell and a slightly later coming BMP pathway. As these path-
ways share many of their signaling components, the integrated
outcome of such combinatorial signaling can be diﬃcult to
predict. The current evolution of molecular and pharmacolog-
ical tools for the dissection of all these pathways promises a
thorough understanding of how cells interpret the intercon-
nected signals from three or four TGF-b family ligands. We
are optimistic that despite the ﬁrm establishment of this signal-
ing pathway in textbooks, the next ﬁve years will oﬀer signiﬁ-
cant revelations that will necessitate a serious rewriting of the
central signaling network that gets mobilized every time a cell
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